Michael F Princiotta

Title: Michael F Princiotta: Innovator in Cancer Immunotherapy

Introduction

Michael F Princiotta is a notable inventor based in Hightstown, NJ (US). He has made significant contributions to the field of cancer immunotherapy, holding a total of 3 patents. His work focuses on developing innovative solutions to combat cancer through immunogenic compositions and methods.

Latest Patents

One of his latest patents is titled "Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof." This patent describes recombinant fusion polypeptides that include one or more antigenic peptides from cancer-associated proteins. These compositions aim to induce an immune response against tumors by utilizing various antigenic peptides, including those that comprise recurrent cancer mutations. Additionally, the patent covers methods for generating these fusion polypeptides and their applications in immunogenic compositions, pharmaceutical compositions, and vaccines.

Another significant patent by Princiotta is "Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof." This disclosure provides delivery vectors that include minigene expression constructs. These constructs are designed to induce an immune response against tumors and can be used for treating and vaccinating subjects with antigen-expressing tumors.

Career Highlights

Throughout his career, Michael F Princiotta has worked with several prominent companies in the biotechnology sector. Notable among these are Advaxis, Inc. and Epivax Therapeutics, Inc. His experience in these organizations has allowed him to further his research and development efforts in cancer treatment.

Collaborations

Michael has collaborated with various professionals in his field, including Robert Petit and Brandon Coder. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Michael F Princiotta is a distinguished inventor whose work in cancer immunotherapy has the potential to make a significant impact on treatment options for patients. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.